Avita Medical (ASX:AVH), a regenerative medicine company focussed on unmet medical needs in burns, chronic wounds, and aesthetics indications, has announced that Dale A. Sander has been appointed its new chief financial officer.
The company said Mr Sander will be responsible for overseeing the global finance and investor relations functions, and aligning them with the company’s commercialisation strategy.
Current CFO, Tim Rooney, has been appointed the company's chief administrative officer, responsible for global operations and supply chain management, human resources, and information technology. Both executives will be based in California.
“These executive changes come at a pivotal time in the transformation of our company,” said Avita CEO, Dr Mike Perry. “Dale has more than 20 years of experience, including serving as CFO of four medical device and pharmaceutical companies as well as eleven years of leading public companies in the CFO role. Dale brings extensive experience in leading both public and private equity offerings, including multiple IPOs in the U.S. and Europe. He also has a strong track record of managing investor relations in these markets as well as in Asia. Dale’s expertise will be critical in supporting our commercialization strategy in advance of our anticipated approval of ReCell in the United States.”
"Tim Rooney, who has been with Avita Medical since 2012 in various key executive roles, will now lead a variety of critical operational and strategic functions," said the company.
“I’m thrilled to continue my work with Avita as part of our senior executive team,” said Mr Rooney. “In my new role, I look forward to continuing my contributions to critical elements in Avita’s growth, especially as we prepare for the anticipated approval of ReCell.”
A premarket approval (PMA) application for the ReCell device was filed with the FDA in September this year. ReCell is a regenerative medicine platform with the potential to offer patients benefits across a broad range of applications including burns, chronic wounds and aesthetics.